Literature DB >> 421718

Decreased half life of cyclophosphamide in patients under continual treatment.

M D'Incalci, G Bolis, T Facchinetti, C Mangioni, L Morasca, P Morazzoni, M Salmona.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 421718     DOI： 10.1016/0014-2964(79)90198-1

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0014-2964            Impact factor:   9.162


× No keyword cloud information.
  25 in total

Review 1.  Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.

Authors:  K L Dechant; R N Brogden; T Pilkington; D Faulds
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

2.  The pharmacokinetics of high dose cyclophosphamide and high dose etoposide.

Authors:  D Cunningham; J Cummings; R B Blackie; L McTaggart; S W Banham; S B Kaye; M Soukop
Journal:  Med Oncol Tumor Pharmacother       Date:  1988

3.  Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors.

Authors:  Fariba Navid; Sharyn D Baker; M Beth McCarville; Clinton F Stewart; Catherine A Billups; Jianrong Wu; Andrew M Davidoff; Sheri L Spunt; Wayne L Furman; Lisa M McGregor; Shuiying Hu; John C Panetta; David Turner; Demba Fofana; Wilburn E Reddick; Wing Leung; Victor M Santana
Journal:  Clin Cancer Res       Date:  2012-11-08       Impact factor: 12.531

Review 4.  Pharmacokinetic drug interactions of commonly used anticancer drugs.

Authors:  F M Balis
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

Review 5.  Metabolism and pharmacokinetics of oxazaphosphorines.

Authors:  A V Boddy; S M Yule
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

6.  Disposition of antipyrine in African patients with Hodgkin's lymphoma.

Authors:  F D Juma
Journal:  Br J Clin Pharmacol       Date:  1987-12       Impact factor: 4.335

Review 7.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

8.  Pharmacokinetics of high-dose cyclophosphamide in patients with metastatic bronchogenic carcinoma.

Authors:  P M Wilkinson; P A O'Neill; N Thatcher; S B Lucas
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

9.  Bioavailability of cyclophosphamide from oral formulations.

Authors:  T Wagner; K Fenneberg
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 10.  Pharmacokinetic optimisation of anticancer therapy.

Authors:  J Liliemark; C Peterson
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.